These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. Vanguri P; Shin ML J Biol Chem; 1988 May; 263(15):7228-34. PubMed ID: 2452821 [TBL] [Abstract][Full Text] [Related]
4. Serum amyloid P component forms a stable complex with human C5b6. Barbashov SF; Wang C; Nicholson-Weller A J Immunol; 1997 Apr; 158(8):3830-5. PubMed ID: 9103450 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies. Hu X; Kang S; Lefort C; Kim M; Jin MM Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6252-7. PubMed ID: 20308586 [TBL] [Abstract][Full Text] [Related]
6. Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly. Würzner R; Mewar D; Fernie BA; Hobart MJ; Lachmann PJ Immunology; 1995 Jun; 85(2):214-9. PubMed ID: 7642210 [TBL] [Abstract][Full Text] [Related]
7. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. Narang A; Qiao F; Atkinson C; Zhu H; Yang X; Kulik L; Holers VM; Tomlinson S J Neuroinflammation; 2017 Jun; 14(1):120. PubMed ID: 28629465 [TBL] [Abstract][Full Text] [Related]
8. Generation of antagonistic monoclonal antibodies against the neoepitope of active mouse interleukin (IL)-18 cleaved by inflammatory caspases. Uchida Y; Nariai Y; Obayashi E; Tajima Y; Koga T; Kawakami A; Urano T; Kamino H Arch Biochem Biophys; 2022 Sep; 727():109322. PubMed ID: 35709966 [TBL] [Abstract][Full Text] [Related]
9. Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Zelek WM; Stott M; Walters D; Harris CL; Morgan BP Immunology; 2018 Nov; 155(3):396-403. PubMed ID: 29981529 [TBL] [Abstract][Full Text] [Related]
10. Bacterial killing by complement requires membrane attack complex formation via surface-bound C5 convertases. Heesterbeek DA; Bardoel BW; Parsons ES; Bennett I; Ruyken M; Doorduijn DJ; Gorham RD; Berends ET; Pyne AL; Hoogenboom BW; Rooijakkers SH EMBO J; 2019 Feb; 38(4):. PubMed ID: 30643019 [TBL] [Abstract][Full Text] [Related]
12. Population-level distribution and putative immunogenicity of cancer neoepitopes. Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567 [TBL] [Abstract][Full Text] [Related]
13. A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Yatime L; Merle NS; Hansen AG; Friis NA; Østergaard JA; Bjerre M; Roumenina LT; Thiel S; Kristensen P; Andersen GR Front Immunol; 2018; 9():2822. PubMed ID: 30555486 [TBL] [Abstract][Full Text] [Related]
14. Paradoxical reconstitution of complement activity following plasma transfusion of an individual with deficiency of the seventh component of complement. Platonov AE; Würzner R; Beloborodov B; Jones AM; Troshansky DV; Vershinina IV; Lachmann PJ; Orren A Immunology; 1994 Jan; 81(1):142-8. PubMed ID: 8132211 [TBL] [Abstract][Full Text] [Related]
15. Blocking antibodies specific for human albumin interfere with the hemolytic activity of the membrane attack complex of complement. Houle JJ; Hoffmann EM Biochem Biophys Res Commun; 1994 Apr; 200(1):135-41. PubMed ID: 8166680 [TBL] [Abstract][Full Text] [Related]
16. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies. Würzner R; Xu H; Franzke A; Schulze M; Peters JH; Götze O Immunology; 1991 Sep; 74(1):132-8. PubMed ID: 1718850 [TBL] [Abstract][Full Text] [Related]
17. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b. Rosenfeld SI; Jenkins DE; Leddy JP J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins. Conde JN; da Silva EM; Allonso D; Coelho DR; Andrade IDS; de Medeiros LN; Menezes JL; Barbosa AS; Mohana-Borges R J Virol; 2016 Nov; 90(21):9570-9581. PubMed ID: 27512066 [TBL] [Abstract][Full Text] [Related]
19. Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity. Mort JS; Flannery CR; Makkerh J; Krupa JC; Lee ER Biochem Soc Symp; 2003; (70):107-14. PubMed ID: 14587286 [TBL] [Abstract][Full Text] [Related]
20. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. Xiong ZQ; Qian W; Suzuki K; McNamara JO J Neurosci; 2003 Feb; 23(3):955-60. PubMed ID: 12574424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]